Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient

被引：15

作者：

Chan, P. A. ^{[1
]}

Connell, N. T.

Gabonay, A. M.

Westley, B. ^{[1
]}

Larkin, J. M. ^{[1
]}

LaRosa, S. P. ^{[1
]}

Chapin, K. ^{[1
,2
]}

Mermel, L. ^{[1
]}

机构：

[1] Brown Univ, Dept Med, Div Infect Dis, Alpert Med Sch, Providence, RI 02912 USA

[2] Rhode Isl Hosp, Dept Pathol, Providence, RI USA

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2010年 / 16卷 / 10期

关键词：

H1N1; immunocompromised; influenza A; oseltamivir; resistance; VIRUS;

D O I：

10.1111/j.1469-0691.2010.03212.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Although neuraminidase inhibitors are active against most 2009-2010 pandemic influenza A (H1N1) swine-origin strains, sporadic cases of oseltamivir resistance have been described. Since April 2009, 54 cases of oseltamivir-resistant H1N1 swine-origin have been reported in the USA (http://www.cdc.gov/flu/weekly/; accessed 1 February 2010). Approximately 1.4% of tested isolates are oseltamivir resistant. We report a patient with an underlying hematological malignancy who was hospitalized with influenza A (H1N1) swine-origin and whose strain developed oseltamivir resistance during therapy.

引用

页码：1576 / 1578

页数：4

共 13 条

[1]

Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P969

[2] Oseltamivir-Resistant Influenza A Pandemic (H1N1) 2009 Virus, Hong Kong, China [J].

Chen, Honglin ;

Cheung, Chung Lam ;

Tai, Hung ;

Zhao, Pengxi ;

Chan, Jasper F. W. ;

Cheng, Vincent C. C. ;

Chan, Kwok-Hung ;

Yuen, Kwok-Yung .

EMERGING INFECTIOUS DISEASES, 2009, 15 (12) :1970-1972

[3]

Englund J., 2009, Morbidity and Mortality Weekly Report, V58, P893

[4] Intravenous Zanamivir for Oseltamivir-Resistant 2009 H1N1 Influenza [J].

Gaur, Aditya H. ;

Bagga, Bindiya ;

Barman, Subrata ;

Hayden, Randall ;

Lamptey, Aubrey ;

Hoffman, James M. ;

Bhojwani, Deepa ;

Flynn, Patricia M. ;

Tuomanen, Elaine ;

Webby, Richard .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (01) :88-89

[5] Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors [J].

Gubareva, LV .

VIRUS RESEARCH, 2004, 103 (1-2) :199-203

[6] Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir [J].

Gubareva, LV ;

Kaiser, L ;

Matrosovich, MN ;

Soo-Hoo, Y ;

Hayden, FG .

JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (04) :523-531

[7] The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo [J].

Ives, JAL ;

Carr, JA ;

Mendel, DB ;

Tai, CY ;

Lambkin, R ;

Kelly, L ;

Oxford, JS ;

Hayden, FG ;

Roberts, NA .

ANTIVIRAL RESEARCH, 2002, 55 (02) :307-317

[8] Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis [J].

Jefferson, Tom ;

Jones, Mark ;

Doshi, Peter ;

Del Mar, Chris .

BMJ-BRITISH MEDICAL JOURNAL, 2009, 339 :1364

[9]

Jurawan R, 2009, NEW ZEAL MED J, V122, P107

[10] Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population [J].

Kharfan-Dabaja, Mohamed A. ;

Velez, Ana ;

Richards, Karla ;

Greene, John N. ;

Field, Teresa ;

Sandin, Ramon .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (01) :124-127

← 1 2 →